Full Research Description
Alan J. Morrison founded Law Offices of Alan J. Morrison, where he specializes in biotechnology and pharmaceutical law. Prior to starting his own firm, he was a partner at the New York firms of Cozen O’Connor; Cohen, Pontani, Lieberman & Pavane LLP; and Cooper & Dunham LLP, and served as in-house counsel at Johnson & Johnson in New Brunswick, New Jersey.
During his career, Alan has engaged in all aspects of patent prosecution, legal opinions, and patent-related regulatory matters and transactions. He has represented corporations, universities and research institutes in acquiring and protecting groundbreaking inventions such as recombinant antibody drugs, catalytic nucleic acids, DNA microarrays, molecular diagnostic methods and kits, pharmaceutical formulations, stem cell-based methods, and small molecule drug synthesis.
Alan has lectured extensively in the United States, Europe, Asia and Africa on various topics in patent and regulatory law, and has written on timely and often controversial topics such as gene patenting and biosimilars law.
He is co-chair emeritus and a founding member of the advisory board for the Bellevue/NYU Program for Survivors of Torture. He has also served on the advisory boards for the Stem Cell Partnering Series and the Columbia University Biotechnology Association.
Alan holds a B.A. in biochemistry from the University of California, Berkeley; an M.S. in biological chemistry from the University of Michigan; an M.Phil. in biochemistry and molecular biophysics from Columbia University; and a J.D. from Yeshiva University.
- Alan J. Morrison (December 2010) Rethinking the Gene Patent Biotechnology Law Report 29(6): 609-614.
- (2010) IP Issues in the Therapeutic Antibody Industry (Chapter 39 of Antibody Engineering),United States subchapter of Patent Enforcement (39.4.13), Springer-Verlag Berlin Heidelberg (Contributor).
- Alan J. Morrison (December 2008/January 2009) Patenting DNA in the United States Managing Intellectual Property
- Alan J. Morrison (October 2007) Biosimilars in the United States: A Brief Look at Where We Are and the Road Ahead Biotechnology Law Report 26(5): 463-468.